Ok. Mine is ProShares Ultra Nasdaq Biotechnology (BIB)
One Year return: 50.27%
Three Year return: 559.82%
Current Top stock holdings:
BIIB Biogen Idec Inc 6.27%
CELG Celgene Corp 5.59%
AMGN Amgen Inc 5.47%
GILD Gilead Sciences Inc 5.34%
Since you have been posting the same sentences daily since Feb 8, can you be more specific?
Accuser of what?
Guilty of what?
Since there are both weekly and monthly options, the options you must be referring to are weeklys. If so, why doesn't GILD have weekly downgrades? And with the stock crashing like it did, this week's CALL options are burnt and worth practically nothing, so there wouldn't need to be a downgrade announced. Plus if you look at the volume/interest of weeklys, it is far less than monthlys. Why not wait until monthlys are about to expire?
I question your knowledge of options trading. So, tell us, who are 'these guys' and who are paying them? And where does your source of these guys being paid come from? I'm curious. Do you work for a firm that does this, know of a firm that does this? If so tell us the names of these firms - not some broad stroke response like hedge fund managers.
applesandspice. I agree 99%. Unfortunately, guidance has been vague to nothing in the past. If this changes...I could only imagine this stock heading north quickly.
I've always held through earnings. Back then I thought... would of, could of, should of. I should have sold some, then bought back in the day after earnings. I'd be better off. Since then, in addition to owning shares, I learned to buy options - more bang for your buck. I'm optimistic with Gilead so I buy calls. Being pessimistic, you'd buy puts. And being pessimistic with ABBV I bought my first puts and made some money. To me, puts is a backwards strategy hoping the stock will drop. I don't hope for any stock to drop. We're all into bettering our future.
This quarter could be different. We see ICPT and BIIB flying. Could that happen with GILD? I'm going to cover my bases. I plan to sell some and hopefully buy back in when there is an early sell off, but I also plan to hold some in case it takes off. I want to be on the train when it leaves the station.
I've read your posts on the ABBV forum and it appears you are heavily invested in ABBV and a bigger pusher of ABBV.
If going head to head with Hep-C, because of less pills, less side effects, more PBMs siding with GILD, and slow start up of VPak, I question VPak long term success. Investing in both GILD and ABBV would be a plus regarding Hep-C, but that is only a part of the puzzle. You need to take into account revenue of their other drugs.
Pipeline: Long term GILD over ABBV.
GILD has a great pipeline with many revenue successful drugs on the market.
As far as ABBV, the patent for their bread and butter revenue drug, Humira, which is projected to be 60% of the company's revenue in 2016, expires in December of 2016. What will replace Humira? It won't be VPak.
I just don't see the excitement and future outlook to see ABBV's price increase as fast as GILD's could. I chose to put my money in GILD, not split it between GILD and ABBV.
And, where did you come up with 1100 scripts. I've read from multiple sources, less than half that amount. Can you provide a link?
Apparently you haven't been following weekly script totals for both companies nor the articles regarding PDMs selecting GILD over ABBV, or you are stuck holding ABBV. Based on your posts, you are most likely a ABBV holder. Hopefully in the future you will choose to do research as I kindly suggested in your other post.
If you don't realize which I doubt you do, these posts of yours are unintelligent and childish. Since we are all just words behind a screen, typed words define us. I suggest clicking on your name and reading all your past posts as if they were someone else's, someone you don't know. How would you define that poster?
Oh, and no one takes your posts seriously, no one is that naive. Everyone knows you are just joking, but no one is laughing. Rather, one quickly surmises you lack investment knowledge.
You can click on the Summary tab above, then click on historical prices down left column. Key in a date range 5 days before and 5 days after each earnings report date, which is after market close on that day. To find dates, go to gileadDOTcom - click on Financial tab at top of page and click Earnings. You would need to dig deeper into news and releases to determine price flow around each of those earnings.
For the past 4 quarters, stock sold off the day after earnings, but then crept back up days and weeks after.
Just like the daily pattern that has been occurring, I believe it will shoot up in the first 1/2-1 hour, then sell off, then rebound back up.
Will that trend continue this quarter, who knows? Will Harvoni and their other drug sales be a grand slam?
I believe longs will be fine. Options traders should be cautious.
What I believe is my feelings alone, so don't take it as advice. I am not an expert, don't claim to be, nor can i predict the future. Good luck in your strategy.
So kim educate us..as you state 'don't include'...
How does a publicly traded company produce an Income Statement and Balance Sheet that is not accurate and is incomplete? You do know public companies are audited, don't you? What would be ABBVs gain to not post accurate sales figures?
Please tell, I want to learn.
kim, do you have inside info to state such? You don't. If you did you would not be posting here. Their quarterly release this morning didn't have a breakdown and you wouldn't know it unless you were a part of ABBV upper management and have the company's detail reports for each drug's costs and sales.
The quarter's results included $48 million from the Viekira Pak, a new hepatitis C medication approved in the U.S. in December.
Someone with script totals can calc per script.
Seeking Alpha article:
The FDA approves Janssen's (NYSE:JNJ) Prezcobix (darunavir/cobicistat) for the treatment, in combination with other antivirals, of adults patients with HIV-1 infection. Darunavir is protease inhibitor (sold as a single agent under the brand name Prezista by Janssen) and cobicistat is a CYP3A4 inhibitor (sold as a single agent under the brand name Tybost by Gilead (NASDAQ:GILD) Sciences).
As of 9:18 am, only 44,291 shares traded in pre-hours. Most of the time around 10:30 is a good sign of the direction the stock is heading.
Article is from businesswire . Just do a search on 'envisionrx gilead' and links to the article will be listed.
1:00p ET January 26, 2015 (Business Wire) Print
EnvisionRx(R), a national, full-service pharmacy benefit management (PBM) company, today announced a partnership with Gilead Sciences Inc., a pioneer in the treatment of the Hepatitis C virus (HCV), to provide availability to HCV infection treatments Sovaldi(R) and Harvoni(TM) for EnvisionRx patients on an exclusive basis.
I am in the Eastern Standard Time zone so markets close at 4:00 for me. As I recall, earnings have always been announced right after close and news is sent immediately (4:01) - initially one liners, then more in detail. 4:30 GILD has a live company meeting and discuss the quarterly earnings.
You can listen in - just go to their website GileadDOTcom or your investment site may provide a #/link.
My TDA account states Earnings on 2/3/15 after Market Central Standard Time
You should keep your and your significant other's bedroom discussions off the forum board.